Now that Vertanical's Exilby has been approved in Germany to treat chronic pain, Clemens Fischer, the pharma billionaire behind it, has set his sights on the U.S. market. ‘There is no plan B for me.'
Will Yakowicz is a Staff Writer at Forbes. He covers topics related to cannabis, gambling, and psychedelics, focusing on the business and regulatory aspects of the cannabis industry. Will's work has been featured in T-SPAN, RealClearMarkets, Forbes, and Forbes Australia.